Compounds > englerin a
Page last updated: 2024-11-13

englerin a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators
FloraRankFlora DefinitionFamilyFamily Definition
PhyllanthusgenusA plant genus of the family EUPHORBIACEAE. Bahupatra (MEDICINE, AYURVEDIC) is prepared from this.[MeSH]Phyllanthaceae[no description available]
Phyllanthus englerispecies[no description available]Phyllanthaceae[no description available]

Cross-References

ID SourceID
PubMed CID46242512
CHEMBL ID2024567
CHEBI ID72441
SCHEMBL ID12280306
MeSH IDM0529336

Synonyms (18)

Synonym
(1r,3ar,4s,5r,7r,8s,8ar)-5-(glycoloyloxy)-7-isopropyl-1,4-dimethyldecahydro-4,7-epoxyazulen-8-yl (2e)-3-phenylacrylate
CHEBI:72441 ,
CHEMBL2024567
englerin a ,
SCHEMBL12280306
(-)-englerin a
gtpl8372
1094250-15-3
Q27077187
(1r,3ar,4s,5r,7r,8s,8ar)-5-(2-hydroxyacetoxy)-7-isopropyl-1,4-dimethyldecahydro-4,7-epoxyazulen-8-yl cinnamate
MS-27966
HY-133168
[(1s,2r,5r,6r,7s,8r,10r)-10-(2-hydroxyacetyl)oxy-1,5-dimethyl-8-propan-2-yl-11-oxatricyclo[6.2.1.02,6]undecan-7-yl] (e)-3-phenylprop-2-enoate
CS-0112862
AKOS040756464
Z4119398124
bdbm50601267
englerin-a

Research Excerpts

Overview

Englerin A (EA) is a potent agonist of tetrameric transient receptor potential canonical (TRPC) ion channels containing TRPC4 and TRPC5 subunits. It is a natural product with a very potent and selective cytotoxicity against renal cancer cells.

ExcerptReferenceRelevance
"Englerin A (EA) is a small-molecule natural product with selective cytotoxicity against renal cancer cells. "( Englerin A Rewires Phosphosignaling via Hsp27 Hyperphosphorylation to Induce Cytotoxicity in Renal Cancer Cells.
Alli-Shaik, A; Gunaratne, J; Lim, Z; Neo, SP; Wee, S, 2022)		3.61
"Englerin A (EA) is a potent agonist of tetrameric transient receptor potential canonical (TRPC) ion channels containing TRPC4 and TRPC5 subunits. "( Englerin A Inhibits T-Type Voltage-Gated Calcium Channels at Low Micromolar Concentrations.
Beck, A; Flockerzi, V; Klugbauer, N; Schneider, JG; Wardas, B, 2023)		3.8
"(-)-Englerin A (EA) is a potent cytotoxic agent against renal carcinoma cells. "( Identification of an (-)-englerin A analogue, which antagonizes (-)-englerin A at TRPC1/4/5 channels.
Beech, DJ; Choidas, A; Christmann, M; Dinkel, K; Habenberger, P; Hahn, S; Klebl, B; Nussbaumer, P; Rubaiy, HN; Seitz, T; Waldmann, H, 2018)		1.34
"Englerin A is a structurally unique natural product reported to selectively inhibit growth of renal cell carcinoma cell lines. "( Englerin A Agonizes the TRPC4/C5 Cation Channels to Inhibit Tumor Cell Line Proliferation.
Amaral, A; Bailey, S; Berellini, G; Bushell, SM; Carson, C; Ding, J; Erdemli, G; George, E; Henault, M; Jain, RK; Ji, N; Ju, H; Krastel, P; Lao, J; Loureiro, JJ; Lubicka, D; Marsh, G; McPate, M; Miranda, N; Pham, H; Raman, P; Ross, NT; Sarber, J; Schumacher, AM; Solomon, JM; Tang, HM; Thomas, E; Tranter, P; Tullai, J; Verkuyl, JM; Xu, L; Yeola, S, 2015)		3.3
"Englerin A is a potent and selective inhibitor of the growth of six human renal cancer cell lines."( A brief synthesis of (-)-englerin A.
Chain, WJ; Li, Z; Nakashige, M, 2011)		1.39
"Englerin A is a natural product with a very potent and selective cytotoxicity against renal cancer cells."( Englerin a selectively induces necrosis in human renal cancer cells.
Chain, WJ; Fash, DM; Li, Z; Nakashige, ML; Ramos, JW; Sulzmaier, FJ, 2012)		2.54

Bioavailability

ExcerptReferenceRelevance
"Synthesis of analogues of englerin A with a reduced propensity for hydrolysis of the glycolate moiety led to a compound which possessed the renal cancer cell selectivity of the parent and was orally bioavailable in mice."( Synthesis of a stable and orally bioavailable englerin analogue.
Beutler, JA; Chain, WJ; Fash, DM; Figg, WD; Hayavi, S; Li, Z; Neckers, L; Peer, CJ; Ramos, JW; Sourbier, C; Sulzmaier, FJ; Talisman, IJ, 2016)		0.99
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
guaiane sesquiterpenoid
cinnamate ester
glycolate ester
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Short transient receptor potential channel 5Homo sapiens (human)EC50 (µMol)0.00760.00760.00760.0076AID1893735
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (14)

Processvia Protein(s)Taxonomy
calcium ion transportShort transient receptor potential channel 5Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationShort transient receptor potential channel 5Homo sapiens (human)
nervous system developmentShort transient receptor potential channel 5Homo sapiens (human)
positive regulation of cell population proliferationShort transient receptor potential channel 5Homo sapiens (human)
positive regulation of peptidyl-threonine phosphorylationShort transient receptor potential channel 5Homo sapiens (human)
neuron differentiationShort transient receptor potential channel 5Homo sapiens (human)
positive regulation of neuron differentiationShort transient receptor potential channel 5Homo sapiens (human)
positive regulation of axon extensionShort transient receptor potential channel 5Homo sapiens (human)
negative regulation of dendrite morphogenesisShort transient receptor potential channel 5Homo sapiens (human)
neuron apoptotic processShort transient receptor potential channel 5Homo sapiens (human)
calcium ion transmembrane transportShort transient receptor potential channel 5Homo sapiens (human)
phosphatidylserine exposure on apoptotic cell surfaceShort transient receptor potential channel 5Homo sapiens (human)
regulation of membrane hyperpolarizationShort transient receptor potential channel 5Homo sapiens (human)
regulation of cytosolic calcium ion concentrationShort transient receptor potential channel 5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
actin bindingShort transient receptor potential channel 5Homo sapiens (human)
calcium channel activityShort transient receptor potential channel 5Homo sapiens (human)
protein bindingShort transient receptor potential channel 5Homo sapiens (human)
clathrin bindingShort transient receptor potential channel 5Homo sapiens (human)
actinin bindingShort transient receptor potential channel 5Homo sapiens (human)
ATPase bindingShort transient receptor potential channel 5Homo sapiens (human)
store-operated calcium channel activityShort transient receptor potential channel 5Homo sapiens (human)
inositol 1,4,5 trisphosphate bindingShort transient receptor potential channel 5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
plasma membraneShort transient receptor potential channel 5Homo sapiens (human)
dendriteShort transient receptor potential channel 5Homo sapiens (human)
growth coneShort transient receptor potential channel 5Homo sapiens (human)
neuronal cell bodyShort transient receptor potential channel 5Homo sapiens (human)
calcium channel complexShort transient receptor potential channel 5Homo sapiens (human)
cation channel complexShort transient receptor potential channel 5Homo sapiens (human)
plasma membraneShort transient receptor potential channel 5Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (34)

Assay IDTitleYearJournalArticle
AID1346575Human TRPC5 (Transient Receptor Potential channels)2015Angewandte Chemie (International ed. in English), Mar-16, Volume: 54, Issue:12
(-)-Englerin A is a potent and selective activator of TRPC4 and TRPC5 calcium channels.
AID1346624Human TRPC4 (Transient Receptor Potential channels)2015Angewandte Chemie (International ed. in English), Mar-16, Volume: 54, Issue:12
(-)-Englerin A is a potent and selective activator of TRPC4 and TRPC5 calcium channels.
AID1301113Growth inhibition of human A498 cells incubated for 48 hrs by sulforhodamine B assay2016Bioorganic & medicinal chemistry letters, 06-01, Volume: 26, Issue:11
Synthesis of a stable and orally bioavailable englerin analogue.
AID660609Growth inhibition of human 786-0 cells after 48 hrs by SRB assay2012Journal of natural products, Mar-23, Volume: 75, Issue:3
Chlorinated englerins with selective inhibition of renal cancer cell growth.
AID1301124Growth inhibition of human Hs 578T cells incubated for 48 hrs by sulforhodamine B assay2016Bioorganic & medicinal chemistry letters, 06-01, Volume: 26, Issue:11
Synthesis of a stable and orally bioavailable englerin analogue.
AID660615Growth inhibition of human TK10 cells after 48 hrs by SRB assay2012Journal of natural products, Mar-23, Volume: 75, Issue:3
Chlorinated englerins with selective inhibition of renal cancer cell growth.
AID1301141Activation of PKC in human 786-0 cells at 10 nM2016Bioorganic & medicinal chemistry letters, 06-01, Volume: 26, Issue:11
Synthesis of a stable and orally bioavailable englerin analogue.
AID1484121Half life in mouse at 1 mg/kg, ip by HPLC-MS analysis2017Journal of natural products, 03-24, Volume: 80, Issue:3
Englerins: A Comprehensive Review.
AID1893740Acute toxicity in mouse assessed as maximum tolerated dose measured for 24 hrs2022ACS medicinal chemistry letters, Sep-08, Volume: 13, Issue:9
Biological Effects of Modifications of the Englerin A Glycolate.
AID1662045Agonist activity at human TRPC4/TRPC1 expressed in HEK293 Tet cells assessed as increase in intracellular calcium level at 0.1 uM measured at 5 secs interval for 300 secs by Fura-2AM dye based fluorescence assay2020ACS medicinal chemistry letters, Sep-10, Volume: 11, Issue:9
Bridgehead Modifications of Englerin A Reduce TRPC4 Activity and Intravenous Toxicity but not Cell Growth Inhibition.
AID1893731Growth inhibition of human A498 cells assessed as cell growth inhibition2022ACS medicinal chemistry letters, Sep-08, Volume: 13, Issue:9
Biological Effects of Modifications of the Englerin A Glycolate.
AID660612Growth inhibition of human CAKI-1 cells after 48 hrs by SRB assay2012Journal of natural products, Mar-23, Volume: 75, Issue:3
Chlorinated englerins with selective inhibition of renal cancer cell growth.
AID1301131Chemical stability in 8% HPBCD in water at 5.7 mg/ml at 4 degC2016Bioorganic & medicinal chemistry letters, 06-01, Volume: 26, Issue:11
Synthesis of a stable and orally bioavailable englerin analogue.
AID1484125Drug level in mouse plasma at 1 mg/kg, ip by HPLC-MS analysis2017Journal of natural products, 03-24, Volume: 80, Issue:3
Englerins: A Comprehensive Review.
AID660613Growth inhibition of human RXF393 cells after 48 hrs by SRB assay2012Journal of natural products, Mar-23, Volume: 75, Issue:3
Chlorinated englerins with selective inhibition of renal cancer cell growth.
AID1662048Agonist activity at human TRPC5 expressed in HEK293 Tet cells assessed as increase in intracellular calcium level at 10 nM measured at 5 secs interval for 300 secs by Fura-2AM dye based fluorescence assay2020ACS medicinal chemistry letters, Sep-10, Volume: 11, Issue:9
Bridgehead Modifications of Englerin A Reduce TRPC4 Activity and Intravenous Toxicity but not Cell Growth Inhibition.
AID1484122Cytotoxicity against human A498 cells assessed as reduction in cell viability2017Journal of natural products, 03-24, Volume: 80, Issue:3
Englerins: A Comprehensive Review.
AID1893735Agonist activity at human TRPC5 stably expressed in HEK293 cells assessed as increase in calcium flux by Fura-2AM dye based fluorescence plate reader assay2022ACS medicinal chemistry letters, Sep-08, Volume: 13, Issue:9
Biological Effects of Modifications of the Englerin A Glycolate.
AID1662042Growth inhibition of human UO31 cells incubated for 48 hrs by sulforhodamine B assay2020ACS medicinal chemistry letters, Sep-10, Volume: 11, Issue:9
Bridgehead Modifications of Englerin A Reduce TRPC4 Activity and Intravenous Toxicity but not Cell Growth Inhibition.
AID1662044Agonist activity at human TRPC4/TRPC1 expressed in HEK293 Tet cells assessed as increase in intracellular calcium level at 1 uM measured at 5 secs interval for 300 secs by Fura-2AM dye based fluorescence assay2020ACS medicinal chemistry letters, Sep-10, Volume: 11, Issue:9
Bridgehead Modifications of Englerin A Reduce TRPC4 Activity and Intravenous Toxicity but not Cell Growth Inhibition.
AID1662046Agonist activity at human TRPC4/TRPC1 expressed in HEK293 Tet cells assessed as increase in intracellular calcium level at 1 uM measured at 5 secs interval for 300 secs in presence of TRPC4/5 antagonist Pico145 by Fura-2AM dye based fluorescence assay2020ACS medicinal chemistry letters, Sep-10, Volume: 11, Issue:9
Bridgehead Modifications of Englerin A Reduce TRPC4 Activity and Intravenous Toxicity but not Cell Growth Inhibition.
AID660614Growth inhibition of human SN12C cells after 48 hrs by SRB assay2012Journal of natural products, Mar-23, Volume: 75, Issue:3
Chlorinated englerins with selective inhibition of renal cancer cell growth.
AID1662041Growth inhibition of human A498 cells incubated for 48 hrs by sulforhodamine B assay2020ACS medicinal chemistry letters, Sep-10, Volume: 11, Issue:9
Bridgehead Modifications of Englerin A Reduce TRPC4 Activity and Intravenous Toxicity but not Cell Growth Inhibition.
AID1301186Growth inhibition of human A498 cells assessed as cell growth at 10 uM incubated for 48 hrs by sulforhodamine B assay relative to control2016Bioorganic & medicinal chemistry letters, 06-01, Volume: 26, Issue:11
Synthesis of a stable and orally bioavailable englerin analogue.
AID660611Growth inhibition of human ACHN cells after 48 hrs by SRB assay2012Journal of natural products, Mar-23, Volume: 75, Issue:3
Chlorinated englerins with selective inhibition of renal cancer cell growth.
AID1893732Growth inhibition of human UO-31 cells assessed as cell growth inhibition2022ACS medicinal chemistry letters, Sep-08, Volume: 13, Issue:9
Biological Effects of Modifications of the Englerin A Glycolate.
AID1662047Acute toxicity in iv dosed mouse assessed as maximum tolerated dose by up and down method2020ACS medicinal chemistry letters, Sep-10, Volume: 11, Issue:9
Bridgehead Modifications of Englerin A Reduce TRPC4 Activity and Intravenous Toxicity but not Cell Growth Inhibition.
AID1301130Toxicity in iv dosed athymic nude mouse up to 96 hrs2016Bioorganic & medicinal chemistry letters, 06-01, Volume: 26, Issue:11
Synthesis of a stable and orally bioavailable englerin analogue.
AID1893733Growth inhibition of human RXF 393 cells assessed as inhibition of cell growth2022ACS medicinal chemistry letters, Sep-08, Volume: 13, Issue:9
Biological Effects of Modifications of the Englerin A Glycolate.
AID1662043Growth inhibition of human RXF393 cells incubated for 48 hrs by sulforhodamine B assay2020ACS medicinal chemistry letters, Sep-10, Volume: 11, Issue:9
Bridgehead Modifications of Englerin A Reduce TRPC4 Activity and Intravenous Toxicity but not Cell Growth Inhibition.
AID660616Growth inhibition of human UO31 cells after 48 hrs2012Journal of natural products, Mar-23, Volume: 75, Issue:3
Chlorinated englerins with selective inhibition of renal cancer cell growth.
AID1301129Toxicity in ip dosed mouse2016Bioorganic & medicinal chemistry letters, 06-01, Volume: 26, Issue:11
Synthesis of a stable and orally bioavailable englerin analogue.
AID1301196Growth inhibition of human Hs 578T cells assessed as cell growth at 10 uM incubated for 48 hrs by sulforhodamine B assay relative to control2016Bioorganic & medicinal chemistry letters, 06-01, Volume: 26, Issue:11
Synthesis of a stable and orally bioavailable englerin analogue.
AID660610Growth inhibition of human A498 cells after 48 hrs2012Journal of natural products, Mar-23, Volume: 75, Issue:3
Chlorinated englerins with selective inhibition of renal cancer cell growth.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (54)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (3.70)29.6817
2010's42 (77.78)24.3611
2020's10 (18.52)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.53

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.53 (24.57)
Research Supply Index4.01 (2.92)
Research Growth Index5.35 (4.65)
Search Engine Demand Index34.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.53)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews6 (11.11%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other48 (88.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
chloroquine
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.		2.0710aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug
beta-lapachone
beta-lapachone: antineoplastic inhibitor of reverse transcriptase, DNA topoisomerase, and DNA polymerase. beta-lapachone : A benzochromenone that is 3,4-dihydro-2H-benzo[h]chromene-5,6-dione substituted by geminal methyl groups at position 2. Isolated from Tabebuia avellanedae, it exhibits antineoplastic and anti-inflammatory activities.		3.3510benzochromenone;
orthoquinones		anti-inflammatory agent;
antineoplastic agent;
plant metabolite
aldosterone
[no description available]		2.61011beta-hydroxy steroid;
18-oxo steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid hormone;
mineralocorticoid;
primary alpha-hydroxy ketone;
steroid aldehyde		human metabolite;
mouse metabolite
fluorescein-5-isothiocyanate
Fluorescein-5-isothiocyanate: Fluorescent probe capable of being conjugated to tissue and proteins. It is used as a label in fluorescent antibody staining procedures as well as protein- and amino acid-binding techniques.. fluorescein 5-isothiocyanate : The 5-isomer of fluorescein isothiocyanate. Acts as a fluorescent probe capable of being conjugated to tissue and proteins; used as a label in fluorescent antibody staining procedures as well as protein- and amino acid-binding techniques.		2.4110fluorescein isothiocyanate
platinum
Platinum: A heavy, soft, whitish metal, resembling tin, with atomic number 78, atomic weight 195.084, symbol Pt. It is used in manufacturing equipment for laboratory and industrial use. It occurs as a black powder (platinum black) and as a spongy substance (spongy platinum) and may have been known in Pliny's time as alutiae.		7.1310elemental platinum;
nickel group element atom;
platinum group metal atom
rhodium
Rhodium: A hard and rare metal of the platinum group, atomic number 45, atomic weight 102.905, symbol Rh.. rhodium atom : A cobalt group element atom of atomic number 45.		2.7730cobalt group element atom
samarium
Samarium: An element of the rare earth family of metals. It has the atomic symbol Sm, atomic number 62, and atomic weight 150.36. The oxide is used in the control rods of some nuclear reactors.		7.0610f-block element atom;
lanthanoid atom
gadolinium
Gadolinium: An element of the rare earth family of metals. It has the atomic symbol Gd, atomic number 64, and atomic weight 157.25. Its oxide is used in the control rods of some nuclear reactors.		2.1710f-block element atom;
lanthanoid atom
gold
Gold: A yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.		2.9840copper group element atom;
elemental gold
iodine
[no description available]		2.0610halide anion;
monoatomic iodine		human metabolite
phenyl acetate
phenyl acetate: The ester formed between phenol and acetic acid. Don't confuse with phenylacetic acid derivatives listed under PHENYLACETATES.. phenyl acetate : An acetate ester obtained by the formal condensation of phenol with acetic acid.		2.0510benzenes;
phenyl acetates
alkenes
[no description available]		3.2710
cobalt
Cobalt: A trace element that is a component of vitamin B12. It has the atomic symbol Co, atomic number 27, and atomic weight 58.93. It is used in nuclear weapons, alloys, and pigments. Deficiency in animals leads to anemia; its excess in humans can lead to erythrocytosis.. cobalt(1+) : A monovalent inorganic cation obtained from cobalt.. cobalt atom : A cobalt group element atom that has atomic number 27.		2.3110cobalt group element atom;
metal allergen		micronutrient
celastrol
[no description available]		3.3510monocarboxylic acid;
pentacyclic triterpenoid		anti-inflammatory drug;
antineoplastic agent;
antioxidant;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
Hsp90 inhibitor;
metabolite
sperm motility inhibitor 2
[no description available]		2.0610
angiotensin ii
Giapreza: injectable form of angiotensin II used to increase blood pressure in adult patients with septic or other distributive shock. Ile(5)-angiotensin II : An angiotensin II that acts on the central nervous system (PDB entry: 1N9V).		2.610amino acid zwitterion;
angiotensin II		human metabolite
ml 204
ML 204: modulates both TRPC4 and TRPC5 channels; structure in first source		2.5420
strychnine
Strychnine: An alkaloid found in the seeds of STRYCHNOS NUX-VOMICA. It is a competitive antagonist at glycine receptors and thus a convulsant. It has been used as an analeptic, in the treatment of nonketotic hyperglycinemia and sleep apnea, and as a rat poison.. strychnine : A monoterpenoid indole alkaloid that is strychnidine bearing a keto substituent at the 10-position.		7.0610monoterpenoid indole alkaloid;
organic heteroheptacyclic compound		avicide;
cholinergic antagonist;
glycine receptor antagonist;
neurotransmitter agent;
rodenticide
farnesyl pyrophosphate
farnesyl pyrophosphate: a sesquiterpene that dimerizes to SQUALENE; RN given refers to cpd without isomeric designation. 2-trans,6-trans-farnesyl diphosphate : The trans,trans-stereoisomer of farnesyl diphosphate.		2.0510farnesyl diphosphateEscherichia coli metabolite;
mouse metabolite
sesquiterpenes
[no description available]		8.9330
naphthoquinones
Naphthoquinones: Naphthalene rings which contain two ketone moieties in any position. They can be substituted in any position except at the ketone groups.		3.3510
sphingosine
sphing-4-enine : A sphingenine in which the C=C double bond is located at the 4-position.. sphingenine : A 2-aminooctadecene-1,3-diol having (2S,3R)-configuration.. sphingoid : Sphinganine, its homologs and stereoisomers, and the hydroxy and unsaturated derivatives of these compounds.. 2-aminooctadec-4-ene-1,3-diol : A 2-aminooctadecene-1,3-diol having its double bond at position 4.		2.1710sphing-4-eninehuman metabolite;
mouse metabolite
sphingosine 1-phosphate
sphingosine 1-phosphate: RN given refers to (R-(R*,S*-(E)))-isomer; RN for cpd without isomeric designation not available 8/89. sphingosine 1-phosphate : A phosphosphingolipid that consists of sphingosine having a phospho group attached at position 1		2.1710sphingoid 1-phosphatemouse metabolite;
signalling molecule;
sphingosine-1-phosphate receptor agonist;
T-cell proliferation inhibitor;
vasodilator agent
cysteine
Cysteine: A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.. L-cysteinium : The L-enantiomer of cysteinium.. cysteine : A sulfur-containing amino acid that is propanoic acid with an amino group at position 2 and a sulfanyl group at position 3.		3.3110cysteiniumfundamental metabolite
1-oleoyl-2-acetylglycerol
[no description available]		2.17101,2-diglyceride
staurosporine
staurosporinium : Conjugate acid of staurosporine.		2.0710ammonium ion derivative
marinomycin a
marinomycin A: antitumor-antibiotic, isolated from the saline culture of a new group of marine actinomycetes; structure in first source		3.2710
Tonantzitlolone A
[no description available]		3.6420fatty acid ester
englerin b
englerin B: from Phyllanthus engleri; structure in first source		4.97110
piperidines
Piperidines: A family of hexahydropyridines.		2.5420
tirandamycin a
tirandamycin A: antibiotic related to streptolydigin		3.2710oxacycle
tirandalydigin
tirandalydigin: structure given in first source; isolated from Streptomyces strain AB 1006A-9		3.2710
tirandamycin b
tirandamycin B: antibiotic related to streptolydigin		3.2710
tonantzitlolone
tonantzitlolone: structure in first source		2.1110
tirandamycin c
tirandamycin C: from a marine-derived Streptomyces sp.; structure in first source		3.2710
ConditionIndicatedRelationship StrengthStudiesTrials
Cancer of Kidney
[description not available]		05.62160
Kidney Neoplasms
Tumors or cancers of the KIDNEY.		05.62160
Anasarca
[description not available]		02.7620
Edema
Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.		02.7620
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.3110
Allodynia
[description not available]		02.3110
Innate Inflammatory Response
[description not available]		02.6120
Ache
[description not available]		02.3110
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.6120
Pain
An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.		02.3110
Albuminuria
The presence of albumin in the urine, an indicator of KIDNEY DISEASES.		02.1710
Kidney Diseases
Pathological processes of the KIDNEY or its component tissues.		02.1710
Cancer of Skin
[description not available]		03.1210
Cancer of the Uterus
[description not available]		03.1210
Leiomyomatosis
The state of having multiple leiomyomas throughout the body. (Stedman, 25th ed)		03.1210
Cancer Syndromes, Hereditary
[description not available]		03.1210
Skin Neoplasms
Tumors or cancer of the SKIN.		03.1210
Uterine Neoplasms
Tumors or cancer of the UTERUS.		03.1210
ER-Negative PR-Negative HER2-Negative Breast Cancer
[description not available]		02.2110
Triple Negative Breast Neoplasms
Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.		02.2110
Adenocarcinoma Of Kidney
[description not available]		03.0340
Carcinoma, Renal Cell
A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.		03.0340
Bone Cancer
[description not available]		02.1310
Ewing Sarcoma
[description not available]		07.1310
Bone Neoplasms
Tumors or cancer located in bone tissue or specific BONES.		02.1310
Sarcoma, Ewing
A malignant tumor of the bone which always arises in the medullary tissue, occurring more often in cylindrical bones. The tumor occurs usually before the age of 20, about twice as frequently in males as in females.		02.1310
Benign Neoplasms
[description not available]		02.9910
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.9910
Acute Lymphoid Leukemia
[description not available]		02.0710
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.		02.0710
Necrosis
The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.		07.0710
Insulin Sensitivity
[description not available]		02.0810
Insulin Resistance
Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.		02.0810